Trigeminal Autonomic Cephalgias (TACs) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Trigeminal Autonomic Cephalgias (TACs) Emerging Therapy and TPP Insights

Thelansis's "Trigeminal Autonomic Cephalgias (TACs) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Trigeminal Autonomic Cephalgias (TACs) Overview

Trigeminal autonomic cephalgias (TACs) are a distinct group of primary headache disorders characterised by strictly unilateral, severe trigeminal distribution pain invariably accompanied by ipsilateral cranial autonomic features - lacrimation, conjunctival injection, rhinorrhoea, ptosis, and eyelid oedema - reflecting activation of the trigeminovascular system and parasympathetic outflow via the sphenopalatine ganglion. The TAC spectrum encompasses cluster headache - the most prevalent and severe form - paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and cranial autonomic features (SUNA), and hemicrania continua, each distinguished by attack duration, frequency, and critically, differential therapeutic responsiveness. Cluster headache presents with excruciating periorbital or temporal attacks lasting 15-180 minutes, occurring in episodic or chronic patterns, with high-flow oxygen and subcutaneous sumatriptan as gold-standard acute therapies and verapamil as first-line prophylaxis; galcanezumab demonstrated efficacy in episodic cluster headache prevention. Paroxysmal hemicrania and hemicrania continua exhibit absolute, diagnostically pathognomonic responses to indomethacin. SUNCT and SUNA respond preferentially to lamotrigine. Secondary TAC mimics - pituitary adenoma, cavernous sinus pathology - mandate neuroimaging exclusion. Emerging neuromodulatory approaches including sphenopalatine ganglion stimulation offer options in refractory cluster headache. Prognosis varies with TAC subtype; accurate diagnosis, subtype-specific management, and multidisciplinary headache specialist involvement are indispensable to optimising patient outcomes and quality of life.

Key Highlights

• In China, diagnosed Cluster Headache cases under Trigeminal Autonomic Cephalalgias (TACs) are estimated at 472,057 patients in 2025, with diagnosis rates reaching nearly 59% of the affected population.
• The diagnosed patient pool is projected to increase to 483,606 patients by 2035, reflecting gradual improvements in neurological awareness and diagnostic capabilities.
• Cluster headache remains one of the most severe and debilitating primary headache disorders, significantly impacting quality of life and productivity.
• Persistent unmet need exists due to underdiagnosis, delayed treatment initiation, limited preventive options, and recurrence of severe headache attacks.
• Increasing focus on CGRP-targeted therapies, neuromodulation approaches, and non-invasive treatment modalities is expected to reshape the TAC treatment landscape.
• Rising awareness among neurologists and expansion of specialized headache centers in China are supporting earlier identification and improved disease management.

Market Overview

• The France Trigeminal Autonomic Cephalalgias market is projected to grow from USD 40 million in 2025 to USD 95 million by 2035, indicating steady market expansion over the forecast period.
• Market growth is driven by:
• Increasing diagnosis and treatment-seeking behavior among cluster headache patients
• Growing adoption of targeted biologics and advanced headache therapies
• Improved access to specialized neurological care and migraine/headache clinics
• Market value is supported by chronic disease recurrence, demand for rapid symptom relief, and premium pricing of innovative therapies.
• Emerging pipeline therapies focused on CGRP inhibition, neurostimulation, and personalized pain management are expected to create significant commercial opportunities.
• Future market growth will depend on therapies capable of reducing attack frequency, improving long-term disease control, and addressing refractory cluster headache cases.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country